Phytopharm Share Discussion Threads

[jondev] 11/1/2013 13:45

Yeah, I just topped up with a few and my buy is showing as a sell?

[cjl2112] 11/1/2013 11:26

Buys showing as sells here on ADVFN, I'm happy to keep adding at these prices.

[mrsapeslaptop] 10/1/2013 19:07

looks like we will be getting selling into the results rather than buying. :))

[ewads] 08/1/2013 19:56

'Parkinson's drug market will reach $3426 million in 2016' predicts new Visiongain report. Dated 7th Jan 2013.

Snippet from above list Cogane

Dr James Evans, a pharmaceutical industry analyst in visiongain, said: "Our analyses identify several new symptomatic treatments for unmet needs in Parkinson's disease (PD), including orthostatic hypotension, Parkinson's-related psychosis and sialorrhoea. However, the R&D pipeline contains more-significant candidates than these, in the form of possible disease-modifying agents that could change the treatment paradigm. These include repurposed existing drugs such as exenatide and isradapine, and new small-molecule agents such as Phytopharm's Cogane and Newron's safinamide. Many possible neuroprotectants are novel agents, including gene therapies, stem cell treatments and peptides.

[nick2412] 07/1/2013 11:49

Surprisingly over-looked by the new year tipsters given the imminent Feb phase 2 trial results. The sector and small cap pharmas seem to have come back in favour in the past few months. Obviously the trial results are pivotal and success would be transformational for the share price. I wonder to what extent they have potential licensing partners lined up in the event of positive results?

The downside with trial failure puts it into the high risk category but the recent developments with ALS and potential funding for trials plus at least a years funding for PYM does give some support. The positive data associated with ALS also hopefully bodes well for the PD trial.

I'd expect to see some interest as Feb approaches and prior to that the solid dosage format for Cogane should have been completed and announced.

[mrsapeslaptop] 03/1/2013 16:32

Biogen drug for ALS has failed.

[nothingtolose] 19/12/2012 16:38

Suspect that will change as folk look to take a position leading into Feb. A lot of eyes watching this one.

[mrsapeslaptop] 19/12/2012 15:32

annual report out. no surprises.

last page interesting. There are only 300 investors who have more than a grands worth of shares. no wonder its quiet on here (at the moment)

[mrsapeslaptop] 19/12/2012 14:09

for those interested.

ALS market size estimated at $2Bn to $4Bn (assuming a 2 year increase in life expectancy)

[mrsapeslaptop] 19/12/2012 12:02

well we are now very de risked, and not dependent only on parkinsons.

I should think we ought to be at 25p by now using comparable valuations to othe uk biotechs.

not long til feb though.

[skinny] 18/12/2012 09:42

That would be my take.

I too have held these since the last century.

[dr biotech] 18/12/2012 09:36

I hold these from ages ago - its in the 90% club for me. I really only continue to hold them until I can write them off as tax loss. Having said that one of my professors at Uni died of MND and any progress in that field would be fantastic.

Todays announcement seems positive enough, but its not game changing. Perhaps the market was expecting something more significant?

[tez123] 18/12/2012 09:26

Can't believe this is down.

[cjl2112] 18/12/2012 07:58

Excellent news well done to all involved.....

[chicken charlie] 18/12/2012 07:26

herw we GO

[squiresquire] 18/12/2012 07:15

utterly brilliant

[squiresquire] 18/12/2012 07:15

utterly brilliant

[tez123] 18/12/2012 07:10

Phytopharm PLC
Cogane in ALS Update
RNS Number : 7480T
Phytopharm PLC
18 December 2012


18th December 2012

COGANE™ IN ALS UPDATE
Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm", the "Group", or the "Company") today announces an update on plans for the further clinical development of CoganeTM as a potential treatment for Amyotrophic Lateral Sclerosis ("ALS").
Earlier this year the Company announced the successful completion of the preclinical evaluation of Cogane™ in ALS, which provided strong support for progression into clinical trials in this indication. Subsequently the Company has been working with a number of leading opinion leaders and charities with an interest in ALS to design a clinical development plan for Cogane™ in ALS.
As part of this process two leading grant-giving bodies, the ALS Association ("ALSA") and the North-East ALS Consortium ("NEALS") in conjunction with Massachusetts General Hospital, have provisionally indicated that they will provide financial and logistic support for future studies of Cogane™ in ALS. Both of these grants are contingent on the Company moving forward with a study in ALS.
The Company is also in discussion with leading regulatory agencies with regard to the design of a clinical development plan for Cogane™ in ALS.
Cogane™ has been granted orphan drug designation for the treatment of ALS in both the US and Europe. Orphan drug designation provides a number of research and development as well as financial advantages to companies developing products targeting the relatively uncommon conditions labelled as "orphan".
In parallel with this work, Phytopharm has been completing a 400-patient, Phase II trial of Cogane™ in early-stage Parkinson's disease (CONFIDENT-PD). All patients have now completed the trial and the Company is on-track to receive the results from this trial in February 2013 as previously announced.
The Company will determine the best way forward for Cogane™ in both Parkinson's disease and ALS once it has analysed the results from the CONFIDENT-PD trial.
Tim Sharpington, Phytopharm CEO, commented "We believe that the pre-clinical data received earlier this year provide a clear rationale for moving forward with clinical trials with Cogane™ in ALS. We are pleased to have received strong support for this programme from leading experts and charities in the field and are working to finalise our development plans with regulatory agencies.
"Whilst the progression of the ALS programme is not wholly dependent on the outcome of the CONFIDENT-PD trial for CoganeTM in Parkinson's Disease, its results may inform the design and conduct of future studies in this setting. We continue to eagerly await the results from this important phase II trial which are expected in February, before making definitive decisions on how best to proceed in both indications, be that alone or in partnership with other companies."


Notes to Editors

Enquiries
Phytopharm plc
Tim Sharpington, CEO
[phone]
Roger Hickling, R&D Director
[phone]

U.K. Investor Relations
FTI Consulting Limited
Ben Atwell
John Dineen
[phone]

Phytopharm plc
Phytopharm plc ("Phytopharm") is a development stage pharmaceutical company developing novel treatments targeting diseases with high levels of unmet need. Our lead series of compounds, the sapogenins (including Cogane™ and Myogane™), has the potential to be a new class of therapy for neurodegenerative diseases including Parkinson's disease (PD), amyotrophic lateral sclerosis ("ALS") and glaucoma.
Phytopharm operates as a virtual company ensuring the majority of our financial resources are focused on our pharmaceutical pipeline. We utilise a network of external scientific and clinical experts to help guide our development projects with our experienced pharmaceutical managers overseeing operations.
Our commercially focused development projects have the potential to produce significant treatment advances in our target areas of neurodegeneration and inflammatory disease. Our products are single chemical entities with novel mechanisms of action protected by strong patent families. Our pipeline has been sourced from our own research activities and from licensing activities, particularly from leading research institutions in China with whom the Company has long-standing relationships.
Our objective is to develop products aimed at major markets with high unmet medical need to key value inflection points before seeking late-stage development and commercial partners as appropriate.
Phytopharm is listed on the premium segment of the Official List of the FSA and traded on the main market of the London Stock Exchange. Further information on Phytopharm is available from the Company's website www.phytopharm.com
About Cogane™
Phytopharm's lead development candidate is Cogane™, a member of the sapogenin class of compounds. It is an orally bioavailable neurotrophic factor modulator that readily crosses the blood‑brain barrier. Cogane™ has demonstrated neuroprotective effects in a range of preclinical models of neurodegenerative diseases. Specifically, CoganeTM has been shown to induce and modulate the production of neurotrophic factors. The neuroprotective and neurotrophic actions of Cogane™ suggest potential beneficial effects in a range of neurodegenerative diseases, including ALS and Parkinson's disease.
Cogane™ has completed long term toxicology studies, has been formulated as a once daily, orally administered therapy and has completed Phase I studies demonstrating a good bioavailability and safety profile.
In addition to the preclinical programme in ALS, Cogane™ is being studied in an ongoing 28 week Phase II clinical trial of patients with early stage Parkinson's disease (CONFIDENT‑PD). The last patient completed this trial in early December 2012.
Cogane™ has been granted Orphan Drug status by both the European Commission and by the US Food & Drug Administration for development in ALS and this will allow significant access to the regulatory authorities for advice and expedited clinical progression as well as providing financial advantages.
About amyotrophic lateral sclerosis (ALS)
ALS, also known as Lou Gehrig's disease, is the most prevalent form of motor neurone disease, which generally strikes people between 40 and 60 years of age. It is estimated that there are over 400,000 patients living with ALS globally. It is a neurodegenerative disease with limited treatment options and poor prognosis. It is characterised by progressive loss of both lower (spinal cord and brain stem) and upper (cerebral cortex) motor neurones, which leads to severe muscle weakness and wasting, followed by paralysis and death, generally caused by respiratory failure. There is an urgent need for the development of new approaches to this devastating condition.
About Orphan Drug Designation
For a product to gain orphan drug status in the United States, the clinical condition must affect less than 200,000 people in the United States. If a product has been granted orphan drug status, FDA will provide assistance in the design of the preclinical and clinical studies needed to achieve marketing approval for the designated clinical condition. Additionally, there are financial incentives available (such as waiver of the fee for the marketing application, currently over $1.5M) and 7 years' market exclusivity (compared to 5 years available for non‑orphan diseases).

[mrsapeslaptop] 17/12/2012 15:37

its always difficult. usually I can only buy £2grand at a time on a quiet day

[gnomet2] 17/12/2012 15:34

And another 4 grands worth. The shares have been hard to get hold of today(edit- in decent quantities), at least from my broker.

[bonzo] 17/12/2012 15:30

Heaven knows we have waited long enough for this... Having lost loads at silly prices, lets hope for a comeback. Great potential here...

[gnomet2] 17/12/2012 14:51

And another 4 grands worth just now. Busy just now - get back to you later.

[mrsapeslaptop] 17/12/2012 14:40

I would have thought so.

its a $Bn market with no treatment. fastrack orphan status could see it on sale at end of PIII if succesful.

RNS definitely needed so we can see if its all funded etc. It not even new news. Its been around for 2 weeks, but only just spotted it as I was awaiting Greensmith's update